ABT

Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2's double beat and guidance raise. ABT's Exact Sciences acquisition strengthens its long-term growth runway, supporting a raised EPS outlook and 10.4% CAGR over the next six years. Despite recent price appreciation, ABT trades below its 5-year forward P/E average, offering a 2.5% yield and a potential 37% upside to a $151 price target.

The NACHC and Abbott Food for Health Initiative is a multi-year "food is medicine" effort to support the integration of nutrition as a foundational component of primary care provided by Community Health Centers (CHCs) across the country Certification program alongside training and resources are designed to help health centers offer real-world approaches that provide healthy food and support to prevent and manage chronic diseases Initiative will reach 1,500+ CHCs providing affordable, comprehensive, effective care to 52.3 million people, including 1 in 7 Americans and 1 in 3 in rural America ABBOTT PARK, Ill. and BETHESDA, Md.

ABT's EPD growth is fueled by emerging-market strength, broad branded generics and healthcare demand, with biosimilars adding opportunities.

"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between Aug. 12-Dec. 4 and log their donation starting Aug. 26 for a Big Ten school at BigTen.org/Abbott or by texting GIVEBLOOD to 222688 (ABBOTT) and select an exclusive, limited-edition T-shirt* while supplies last The movement aims to fuel a new generation of blood donors at a time when 2.5 million donations — nearly a quarter of all donations — come from people over the age of 65 ABBOTT PARK, Ill. and ROSEMONT, Ill.

Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health.

Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.

Investors interested in stocks from the Medical - Products sector have probably already heard of Envista (NVST) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside.

ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.